Acta Neurologica Belgica

, Volume 113, Issue 1, pp 3–6 | Cite as

Nicardipine in the treatment of aneurysmal subarachnoid haemorrhage: a meta-analysis of published data

  • Ren-qiang Huang
  • Fu-gang Jiang
  • Zi-min Feng
  • Tian-yi Wang
Original Article


Nicardipine is a dihydropyridine-type Ca2+ channel blocker with a powerful antihypertensive activity and a unique cerebrovascular profile. Recent studies have examined nicardipine for the treatment of patients with aneurysmal subarachnoid haemorrhage (SAH), but have shown inconsistent results. In the current study, a meta-analysis was performed to assess the clinical effectiveness of nicardipine in the prevention of cerebral vasospasm in patients who had suffered from aneurysmal SAH. Medline, EMBASE, and PubMed databases were searched for the controlled trials evaluating nicardipine for treating SAH after a ruptured aneurysm, without language restrictions. Moreover, a manual search of the bibliographies of relevant articles was also conducted. Two researchers of the present study independently performed the literature search and the data extraction. The meta-analyses were performed using the software RevMan 4.2.10 (provided by the Cochrane Collaboration, Oxford, UK). Five published manuscripts involving 1,154 patients were included in this meta-analysis. Nicardipine infusion reduced the risk of poor outcome (death, vegetative state, or dependency) and mortality, with an odds ratio (OR) of 0.58 [95 % confidence interval (CI) 0.37–0.90] and 0.45 (95 % CI 0.15–1.29), respectively. This meta-analysis suggests that nicardipine therapy reduces the likelihood of poor outcome and mortality in patients after aneurysmal SAH.


Meta-analysis Nicardipine Subarachnoid haemorrhage Delayed cerebral ischaemia 



We gratefully acknowledge the Guilin 181st Hospital for financially supporting this research. The funding source had no involvement in the research design, collection, analysis, and interpretation of data in writing the report or in the decision to submit the article for publication.


  1. 1.
    Barker FG II, Ogilvy CS (1996) Efficacy of prophylactic nimodipine for delayed ischemic deficit after subarachnoid hemorrhage: a meta-analysis. J Neurosurg 84:405–414PubMedCrossRefGoogle Scholar
  2. 2.
    Barth M, Capelle HH, Weidauer S et al (2007) Effect of nicardipine prolonged-release implants on cerebral vasospasm and clinical outcome after severe aneurysmal subarachnoid haemorrhage: a prospective, randomized, double-blind phase IIa study. Stroke 38:330–336PubMedCrossRefGoogle Scholar
  3. 3.
    Dorhout Mees SM, Rinkel GJ, Feigin VL et al (2007) Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 3:CD000277PubMedGoogle Scholar
  4. 4.
    Epstein BJ, Vogel K, Palmer BF (2007) Dihydropyridine calcium channel antagonists in the management of hypertension. Drugs 67:1309–1327PubMedCrossRefGoogle Scholar
  5. 5.
    Haley EC Jr, Kassell NF, Torner JC (1993) A randomized controlled trial of high-dose intravenous nicardipine in aneurysmal subarachnoid haemorrhage. A report of the Cooperative Aneurysm Study. J Neurosurg 78:537–547PubMedCrossRefGoogle Scholar
  6. 6.
    Harrod CG, Bendok BR, Batjer HH (2005) Prediction of cerebral vasospasm in patients presenting with aneurysmal subarachnoid hemorrhage: a review. Neurosurgery 56:633–654PubMedCrossRefGoogle Scholar
  7. 7.
    Hedges LV (1994) Fixed effects models. In: Cooper H, Hedges LV (eds) The handbook of research synthesis. Russell Sage Foundation, New York, pp 285–299Google Scholar
  8. 8.
    Huang J, van Gelder JM (2002) The probability of sudden death from rupture of intracranial aneurysms: a meta-analysis. Neurosurgery 51:1101–1105PubMedCrossRefGoogle Scholar
  9. 9.
    Kasuya H (2011) Clinical trial of nicardipine prolonged-release implants for preventing cerebral vasospasm: multicenter cooperative study in Tokyo. Acta Neurochir Suppl 110:165–167PubMedGoogle Scholar
  10. 10.
    Kasuya H, Onda H, Sasahara A et al (2005) Application of nicardipine prolonged-release implants: analysis of 97 consecutive patients with acute subarachnoid haemorrhage. Neurosurgery 56:895–902PubMedGoogle Scholar
  11. 11.
    Keyrouz SG, Diringer MN (2007) Clinical review: prevention and therapy of vasospasm in subarachnoid haemorrhage. Crit Care 4:211–220Google Scholar
  12. 12.
    Krischek B, Kasuya H, Onda H et al (2007) Nicardipine prolonged-release implants for preventing cerebral vasospasm after subarachnoid haemorrhage: effect and outcome in the first 100 patients. Neurol Med Chir (Tokyo) 47:389–394CrossRefGoogle Scholar
  13. 13.
    Lee KH, Lukovits T, Friedman JA (2006) “Triple-H” therapy for cerebral vasospasm following subarachnoid hemorrhage. Neurocrit Care 4:68–76PubMedCrossRefGoogle Scholar
  14. 14.
    Liu-Deryke X, Rhoney DH (2006) Cerebral vasospasm after aneurysmal subarachnoid haemorrhage: an overview of pharmacologic management. Pharmacotherapy 26:182–203PubMedCrossRefGoogle Scholar
  15. 15.
    Raudenbush SW (1994) Random effects models. In: Cooper H, Hedges LV (eds) The handbook of research synthesis. Russell Sage Foundation, New York, pp 301–321Google Scholar
  16. 16.
    Rinkel GJ (2008) Medical management of patients with aneurysmal subarachnoid haemorrhage. Int J Stroke 3:193–204PubMedCrossRefGoogle Scholar
  17. 17.
    Rinkel GJE, Feigin VL, ALGRA A et al (2005) Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 1:CD000277PubMedGoogle Scholar
  18. 18.
    Sabbatini M, Strocchi P, Amenta F (1995) Nicardipine and treatment of cerebrovascular diseases with particular reference to hypertension-related disorders. Clin Exp Hypertens 17:719–750PubMedCrossRefGoogle Scholar
  19. 19.
    Tejada JG, Taylor RA, Ugurel MS et al (2007) Safety and feasibility of intra-arterial nicardipine for the treatment of subarachnoid haemorrhage-associated vasospasm: initial clinical experience with high-dose infusions. AJNR Am J Neuroradiol 28:844–848PubMedGoogle Scholar
  20. 20.
    van Gijn J, Rinkel GJ (2001) Subarachnoid haemorrhage: diagnosis, causes and management. Brain 124:249–278PubMedCrossRefGoogle Scholar
  21. 21.
    Wang J, Ho L, Chen L et al (2007) Valsartan lowers brain β-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J Clin Invest 117:3393–3402PubMedCrossRefGoogle Scholar
  22. 22.
    Weyer GW, Nolan CP, Macdonald RL (2006) Evidence-based cerebral vasospasm management. Neurosurg Focus 21:E8PubMedCrossRefGoogle Scholar
  23. 23.
    Zhao XD, Zhou YT, Zhang X et al (2010) A meta analysis of treating subarachnoid hemorrhage with magnesium sulfate. J Clin Neurosci 16:1394–1397CrossRefGoogle Scholar

Copyright information

© Belgian Neurological Society 2012

Authors and Affiliations

  • Ren-qiang Huang
    • 1
  • Fu-gang Jiang
    • 1
  • Zi-min Feng
    • 1
  • Tian-yi Wang
    • 1
  1. 1.Department of NeurosurgeryGuilin 181st Hospital, School of Medicine, Southern Medical University (Guangzhou)GuilinChina

Personalised recommendations